Muna Al-Khaifi, GP Oncologist at Mount Sinai Hospital (Toronto), shared a post by David Langelier, Medical Doctor at Alberta Health Services, on LinkedIn, adding:
”Chemotherapy-induced peripheral neuropathy (CIPN) remains one of the most common and persistent long-term side effects of cancer treatment, affecting quality of life, physical function, independence, and the ability to remain active. Building high-quality evidence on exercise as a management strategy has the potential to improve care for countless cancer survivors.
Thrilled to be a Co-I on this CIHR-funded project, and looking forward to seeing the results and their impact on survivorship care. Congratulations again to Jennifer Jones , and the entire investigative team!”
Quoting David Langelier‘s post:
”I’m excited to announce our research on exercise in the management of persistent chemotherapy induced peripheral neuropathy (CIPN) has been awarded from the Canadian Institutes of Health Research / Instituts de recherche en santé du Canada. Did you know two thirds of patients who receive neurotoxic chemotherapy will develop CIPN and while symptoms improve for some, residual symptoms impacting daily life persist for many.
A special thanks to Jennifer Jones leadership, Michelle Nadler, and Eric Antonen, MSc pursuing his PhD with this work. Thanks to all the co-investigators, collaborators and especially patient partners who have made this possible.
While this project will take place Princess Margaret Cancer Centre results will inform care nationwide! Stay tuned as we explore opportunities with this trial in Alberta.”
Other articles about CIPN on OncoDaily.